The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Detection of sensitizing and resistance EGFR mutations from circulating tumor DNA (ctDNA) in blood using multiplexed next-generation sequencing in patients with advanced EGFR-mutant lung adenocarcinoma.
Sarah B. Goldberg
Consultant or Advisory Role - Boehringer Ingelheim
Research Funding - AstraZeneca
Azeet Narayan
No relevant relationships to disclose
Nicholas J. Carriero
No relevant relationships to disclose
Roxanne Nemati
No relevant relationships to disclose
Ananth Bommakanti
No relevant relationships to disclose
Anna Wurtz
No relevant relationships to disclose
Daniel J Boffa
No relevant relationships to disclose
Roy H. Decker
No relevant relationships to disclose
Roy S. Herbst
No relevant relationships to disclose
Juliane M. Juergensmeier
Research Funding - AstraZeneca
Katerina A Politi
Consultant or Advisory Role - Takeda
Other Remuneration - MolecularMD
Scott N. Gettinger
No relevant relationships to disclose
Abhijit Patel
Research Funding - AstraZeneca